Related Experiment Video

Updated: Jul 5, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K

Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis

Jin Sun Kim1, Rohit Gupta2

  • 1Department of Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA 19140, USA.

Journal of Clinical Medicine
|January 11, 2024
PubMed

Insights

Fibrotic pulmonary sarcoidosis is a severe lung condition with limited research. This review explores recent advancements in understanding its mechanisms, prognosis, and treatments for better patient outcomes.

Area of Science:

  • Pulmonology
  • Rheumatology
  • Immunology

Background:

  • Fibrotic pulmonary sarcoidosis is an uncommon but severe manifestation of sarcoidosis.
  • It is associated with significant morbidity and mortality.
  • Current knowledge on its pathogenesis and management is limited.

Purpose of the Study:

  • To review recent developments in fibrotic pulmonary sarcoidosis.
  • To enhance understanding of its underlying mechanisms and prognosis.
  • To explore potential treatment modalities and patient quality of life.

Main Methods:

  • Literature review of recent studies on fibrotic pulmonary sarcoidosis.
  • Analysis of current research on pathogenesis, prognosis, and treatment.
  • Identification of knowledge gaps and areas for future investigation.

Main Results:

  • Recent research has begun to shed light on fibrotic pulmonary sarcoidosis.
  • Understanding of disease mechanisms and prognosis is improving.
  • New therapeutic strategies and insights into patient quality of life are emerging.

Conclusions:

  • Further research is crucial for fibrotic pulmonary sarcoidosis.
  • Targeted therapies and lung transplantation are key areas for investigation.
  • Improving patient quality of life remains a primary goal in managing this condition.
Keywords:
advanced pulmonary sarcoidosisfibrotic pulmonary sarcoidosispulmonary fibrosissarcoidosis

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

446
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

175

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
275
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
164
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
179